Abstract:HomeStrokeVol. 44, No. 9Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China” Meijuan Zhang, MD, PhD and Yun Xu, MD, PhD Meijuan ZhangMeijuan Zhang Department of Neurology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, PR China Search for more papers by this author and Yun XuYun Xu Department of Neurology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, PR China Search for more papers by this author Originally published13 Aug 2013https://doi.org/10.1161/STROKEAHA.113.002158Stroke. 2013;44:e108Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2013: Previous Version 1 We thank Jia et al for their valuable comments regarding our recently published article.1 This prospective study enrolled 259 patients with acute ischemic stroke and found that CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) genotypes had significant impact on clopidogrel response and prognosis of patients with stroke.We have to clarify that the National Institutes of Health Stroke Scale and modified Rankin Scale score in our study were used to evaluate the therapeutic effect of clopidogrel at 3 and 6 months after treatment. In addition to coagulation, platelets also release abundant proinflammatory cytokines that aggravate the pathogenic progress of ischemic injury. Substantial evidence demonstrated that clopidogrel application diminished inflammatory mediators, including C-reactive protein.2 Meanwhile, clopidogrel was also reported to inhibit leukocyte infiltration and decrease the expression of chemotactic factors in inflammatory diseases.3 These results may reflect an early beneficial effect of clopidogrel in patients with stroke. In addition, the latest US guidelines for the early management of patients with acute ischemic stroke also accepted and presented data about beneficial effects of antiplatelet agents in acute stroke assessed by modified Rankin Scale.4 Thus, our data should not be interpreted in the way that CYP2C19 loss-of-function allele is associated with increased risk of recurrent stroke events. The role of clopidogrel polymorphisms in stroke recurrence is an interesting question which we have devoted much time to elicit in recent years. However, we have not ceased our follow-up for it calls for much longer time period than this study.Currently, it is widely accepted that CYP2C19 loss-of-function allele is a major determinant of clopidogrel responsiveness not only in patients with cardiovascular and cerebrovascular diseases, but also in healthy volunteers. However, there is no definitive evidence linking ex vivo platelet aggregation measurements to clinical outcome, and it is still unclear how patients should be managed based on these test results. One of the major problems is lack of confident parameters about activity of clopidogrel in vivo. Nowadays, several platelet function tests that measure the downstream response of clopidogrel on P2Y12 receptor are available, including light transmittance aggregometry, VerifyNow test, and vasodilator-stimulated phosphoprotein phosphorylation analysis.5 These platelet function tests ex vivo lack universal standards and sometimes hardly reflect the real response of clopidogrel in vivo. In our study, we used ADP-induced light transmittance aggregometry assay and found that there were no differences in the average uninhibited baseline platelet functional response to ADP between responders and nonresponders (data not shown). We also evaluated the association between platelet aggregation and stroke outcome, which showed that patients with high platelet aggregation reactivity had bad outcome (data not shown). However, the plasma levels of clopidogrel and its active metabolite in each genotype were not detected in our study. We initially provided evidence that CYP2C19 genotypes had substantial impact on the prognosis of patients with acute stroke when applying clopidogrel. Further studies devoted to establish reliable parameters of clopidogrel response in vivo and verify our findings in multicenter randomized and long-term trials may help develop clinical decisions based on CYP2C19 polymorphisms.Meijuan Zhang, MD, PhDYun Xu, MD, PhDDepartment of NeurologyDrum Tower HospitalNanjing University Medical SchoolNanjing, PR ChinaDisclosuresNone.FootnotesStroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited. References 1. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Stroke. 2013; 44:1717–1719.LinkGoogle Scholar2. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.Vasc Med. 2007; 12:113–122.CrossrefMedlineGoogle Scholar3. Liu O, Jia L, Liu X, Wang Y, Wang X, Qin Y, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression.PLoS One. 2012; 7:e51707.CrossrefMedlineGoogle Scholar4. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2013; 44:870–947.LinkGoogle Scholar5. Price MJ, Barker CM. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.Biomark Med. 2011; 5:43–51.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails September 2013Vol 44, Issue 9 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.113.002158PMID: 23943214 Originally publishedAugust 13, 2013 PDF download Advertisement SubjectsTreatment

Letter by L. Schlemm and E. Schlemm Regarding Article, "Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity".

Response by Siegerink et al to Letter Regarding Article, "Association Between High-Sensitivity Cardiac Troponin and Risk of Stroke in 96 702 Individuals: A Meta-Analysis".

Letter by Zhu et al Regarding Article, "Atrial Fibrillation Known Before or Detected After Stroke Share Similar Risk of Ischemic Stroke Recurrence and Death".

Letter by Diplomatico and Barbi Regarding Article, "Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association".

Letter by Mulder et al Regarding Article, "2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: a Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association".

The Use of Oral Suspension and Rationally Prescribing Alternatives May Be Supplemental to the Implementation of Clopidogrel New Algorithm Comprising CYP2C19 Pharmacogenetics and Drug Interactions

Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China”

Response by Hawe et al to Letter Regarding Article, "Taking Proportional Out of Stroke Recovery".

Letter by Chen Et Al Regarding Article, “neurological, Functional, and Cognitive Stroke Outcomes in Mexican Americans”

Letter by Mishra et al Regarding Article, "Infection as a Stroke Trigger: Associations Between Different Organ System Infection Admissions and Stroke Subtypes".

Letter by Ye and Chen Regarding Article, "Influence of Hemoglobin Concentration on Stroke Recurrence and Composite Vascular Events".

Letter by Xu Regarding Article, "IL (Interleukin)-15 Bridges Astrocyte-Microglia Crosstalk and Exacerbates Brain Injury Following Intracerebral Hemorrhage".

CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study

Correction To: Use of Oral Anticoagulant Drugs is Associated with Carotid Intraplaque Hemorrhage in Atherosclerosis Patients: a Meta-Analysis

Letter by Zhang et al Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?”

Association of CYP2C19 Genotype and Platelet Responsiveness with Clinical Efficacy of Clopidogrel Therapy in Patients with Arteriosclerosis Obliterans after Stent Implantation

Association Between CYP2B6 Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack

The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence

Efficacy of Dual Antiplatelet therapy depending on hsCRP levels and CYP2C19 Genotype

Effect of CYP2C192 and 3 on clinical outcome in ischemic stroke patients treated with clopidogrel.

Ticagrelor–Aspirin Versus Clopidogrel–Aspirin Among CYP2C19 Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial